• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
  •   LillOA Home
  • Liste des unités
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Nasal nanovaccines
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique: Article de synthèse/Review paper
DOI :
10.1016/j.ijpharm.2017.07.012
PMID :
28698066
Permalink :
http://hdl.handle.net/20.500.12210/11287
Title :
Nasal nanovaccines
Author(s) :
Bernocchi, Beatrice [Auteur]
Carpentier, Rodolphe [Auteur] refId
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Betbeder, Didier [Auteur] refId
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center - U 995 [LIRIC]
Journal title :
International journal of pharmaceutics
Abbreviated title :
Int. J. Pharm.
Volume number :
530
Pages :
128-138
Publication date :
2017-09-15
ISSN :
0378-5173
English keyword(s) :
NALT
Vaccine delivery
Nasal vaccines
Nanoparticles
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Nasal administration of vaccines is convenient for the potential stimulation of mucosal and systemic immune protection. Moreover the easy accessibility of the intranasal route renders it optimal for pandemic vaccination. ...
Show more >
Nasal administration of vaccines is convenient for the potential stimulation of mucosal and systemic immune protection. Moreover the easy accessibility of the intranasal route renders it optimal for pandemic vaccination. Nanoparticles have been identified as ideal delivery systems and adjuvants for vaccine application. Heterogeneous protocols have been used for animal studies. This complicates the understanding of the formulation influence on the immune response and the comparison of the different nanoparticles approaches developed. Moreover anatomical and immunological differences between rodents and humans provide an additional hurdle in the rational development of nasal nanovaccines. This review will give a comprehensive expertise of the state of the art in nasal nanovaccines in animals and humans focusing on the nanomaterial used.Show less >
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Collections :
  • Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Research team(s) :
Therapeutic innovation targetting inflammation
Submission date :
2019-05-17T13:14:43Z
Université de Lille

Mentions légales
Accessibilité : non conforme
Université de Lille © 2017